scispace - formally typeset
H

Hisashi Uhara

Researcher at Sapporo Medical University

Publications -  178
Citations -  3068

Hisashi Uhara is an academic researcher from Sapporo Medical University. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 27, co-authored 152 publications receiving 2444 citations. Previous affiliations of Hisashi Uhara include Shinshu University.

Papers
More filters
Journal ArticleDOI

Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.

TL;DR: The prompt and correct recognition of MG following treatment with immune checkpoint inhibitors in patients with cancer is important and postintervention status showed that pharmacologic remission or minimal manifestations were obtained in 4 patients; however, 2 patients died.
Journal ArticleDOI

Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma

TL;DR: An 81-year-old woman with metastatic melanoma, in whom myasthenia gravis and rhabdomyolysis developed after nivolumab monotherapy, was reported, strongly suggesting that the myasta gravis was a nivolinumab-related immune adverse event.
Journal ArticleDOI

Key points in dermoscopic differentiation between early acral melanoma and acral nevus.

TL;DR: The three‐step algorithm for the management of acral melanocytic lesions, which surely aids us in effectively detecting early acrals melanoma and in reducing unnecessary resection of benign nevus is described.
Journal ArticleDOI

Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level.

TL;DR: Melanoma cells show clonal heterogeneity and CTC genotyping may be crucial for successful molecular-targeted therapy, and polyclonal BRAF mutations were identified in one patient and concomitant mutations in BRAF and KIT were identify in another patient.
Journal ArticleDOI

A proposal for a TNM staging system for extramammary Paget disease: Retrospective analysis of 301 patients with invasive primary tumors.

TL;DR: A TNM staging system for EMPD is proposed using simple factors for classification that could provide important prognostic information in managing EMPD and accumulation of more patient data and further revision of the system are required.